Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by Stanford University.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00695916
First received: June 10, 2008
Last updated: December 12, 2008
Last verified: December 2008

June 10, 2008
December 12, 2008
Not Provided
Not Provided
To determine whether pre-lumpectomy breast MRI reduces the frequency of repeat lumpectomy in women with DCIS < 5 cm or T1 or T2 invasive breast cancer
Same as current
Complete list of historical versions of study NCT00695916 on ClinicalTrials.gov Archive Site
  • To determine how often MRI will detect occult multifocal or multicentric disease
  • To determine how often MRI will miss occult DCIS or invasive cancer subsequently detected on surgical pathology
  • To determine the frequency with which breast MRI changes the surgical plan
  • To determine the frequency of false positive MRI findings requiring biopsy
  • To measure whether MRI reduces the frequency of repeat lumpectomy to a greater extent in women with mammographically dense vs fatty breasts
  • To measure whether preoperative MRI is associated with enhanced postoperative cosmesis
  • To measure whether preoperative MRI alters cost of care
  • To measure the degree and extent to which preoperative MRI lengthens the time required to deliver care
  • To measure whether preoperative MRI increases the rate of patient directed ("unnecessary") mastectomy
  • To measure whether MRI decreases the risk of ipsilateral breast tumor recurrence
  • To measure disease-free survival without/with preoperative breast MRI
  • To measure overall survival without/with preoperative MRI
Same as current
Not Provided
Not Provided
 
MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery
Randomized Trial of Breast MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery

To see if performing breast MRI before a lumpectomy will help the surgeon successfully remove the entire cancer with normal tissue margins in a single operation thereby reducing the need for additional surgical procedures. The study will also measure how well MRI can find unsuspected cancers in the same breast as the known cancer; how well MRI will find unsuspected cancers in the opposite breast; how often MRI will generate false positive MRI findings; whether routinely incorporating breast MRI delays care or adds unnecessary cost; and, whether breast MRI is able to reduce the frequency of cancer recurrence in the treated breast or elsewhere in the body.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Breast Cancer
Procedure: Breast MRI
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
180
Not Provided
Not Provided

Inclusion Criteria:

  • DCIS less than 5 cm. T1/T2 invasive breast cancer. Patient is a suitable candidate for breast conservation and wishes this as the primary clinical approach
  • No breast MRI within the past year. Prior core biopsy, but no prior excision allowed. Patient has completed conventional imaging workup with mammography ultrasound as indicated and there is no clinical indication for breast MRI.
  • Women with age >= 18. No ethnic restrictions.
  • No life expectancy restrictions.
  • Performance status not a factor.
  • No requirements for organ or marrow function.
  • Ability to understand and the willingness to sign a written informed consent document.&#xA;

Exclusion Criteria:

  • Patient is unable to complete a breast MRI due to such factors as hardware and claustrophobia.
  • No limitations as to other investigational agents. Patients who have received neoadjuvant chemotherapy will not be included in the study due to the limitations of MRI interpretation after neoadjuvant chemotherapy and because this represents a distinct scenario for interpretation of breast MRI in comparison with untreated patients.
  • There are no comorbidities that would preclude entry into the study unless the patient is unable to lay still for breast MRI scanning.
  • There are fewer reactions to MRI contrast media, but if there is such a history, the patient will be excluded from consideration.
  • There are no exclusion criteria based on concomitant medications.
  • There are no other agent specific exclusion criteria.
  • Pregnancy is considered a contraindication given the uncertain effects of breast MRI on the fetus.
  • Cancer survivors are candidates for the study unless the patient has a prior ipsilateral breast tumor.
Female
18 Years and older
No
Contact: Sally Bobo (650) 736-1472 sbobo@stanford.edu
United States
 
NCT00695916
SU-12102007-930, 98272, BRSNSTU0025
Not Provided
Not Provided
Stanford University
Not Provided
Principal Investigator: Frederick M. Dirbas Stanford University
Stanford University
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP